Moderna and Merck are preparing to present detailed Phase 3 clinical trial results for their experimental personalized melanoma vaccine on Saturday, October 24, 2026, at the European Society for Medical Oncology (ESMO) Congress in Madrid, according to Morningstar. The upcoming presentation will reveal just how well the customized mRNA treatment, combined with Merck's immunotherapy drug Keytruda, kept high-risk skin cancer from returning after surgery compared to Keytruda alone.

While the two companies announced on August 19, 2026, that the late-stage study met its primary goals of preventing cancer recurrence and distant spread, they have not yet shared the specific numerical results. Oncologists, patients, and healthcare analysts are closely watching the Madrid conference, which runs from October 23 to October 27, 2026, to see whether the data support bringing the first-of-its-kind therapy into routine medical care.

How the Personalized mRNA Therapy Works

Unlike traditional preventive vaccines given to healthy individuals to stop an infection before it starts, the experimental shot—known scientifically as intismeran autogene, or mRNA-4157/V940—is a therapeutic treatment designed for patients who have already been diagnosed with stage IIB through IV cutaneous melanoma and have had their tumors surgically removed, as noted in reporting from Becker's Hospital Review.

Each dose is custom-built for a single patient. After a surgeon removes a patient's melanoma tumor, scientists analyze the genetic makeup of both the tumor tissue and a blood sample, according to Star News Group. They identify specific mutated proteins unique to that tumor, called neoantigens, and encode up to 34 of them into an mRNA strand. The entire custom manufacturing process takes about six weeks, as reported by Morningstar.

Dr. Janice Mehnert, an oncologist and director of melanoma and cutaneous medical oncology at NYU Langone Health's Perlmutter Cancer Center who helped lead the research, explained that the vaccine works alongside pembrolizumab, sold under the brand name Keytruda. Because each batch is tailored to an individual's specific mutations, it cannot be given to anyone else.

"The immunotherapy wakes up the immune system; it invigorates it because a lot of the time cancer develops because your immune system got a little lazy, fell asleep at the wheel," Mehnert told Star News Group. "So the immunotherapy takes the brakes off the immune system and wakes it up to get rid of the cancer, but what the vaccine does is it gives your immune system a map or a blueprint to try and hunt down the cancer cells that are hiding."

Inside the Phase 3 Trial and Earlier Benchmarks

The upcoming presentation focuses on the Phase 3 trial known as INTerpath-001. According to BioSpace, the study enrolled 1,137 patients with resected high-risk melanoma. Participants were randomly assigned on a 2-to-1 basis to receive either up to nine doses of the custom vaccine every three weeks alongside Keytruda for up to a year, or Keytruda alone for roughly one year following surgery.

In August, the companies confirmed that an interim analysis showed the combination met its primary endpoint of recurrence-free survival—the length of time a patient lives without signs or symptoms of the cancer returning—as well as a key secondary endpoint measuring survival without distant metastases. However, differing reports and public discussions have sometimes blurred the lines between this large trial and an earlier, smaller study.

Specifically, widely cited figures showing a 49% lower relative risk of recurrence or death (a hazard ratio of 0.51) and a 59% lower relative risk of distant metastasis or death (a hazard ratio of 0.411) after five years of follow-up come from the earlier Phase 2b KEYNOTE-942 study of 157 patients, according to BioSpace and ApoApe News. An exploratory analysis from that June data readout also noted a 53% improvement in overall survival. Importantly, those relative risk reductions measure hazard rates over time rather than proving that the same percentage of patients were permanently cured.

While the companies have characterized the newer Phase 3 results as statistically significant and clinically meaningful, STAT and Morningstar note that the exact magnitude of benefit in the larger 1,137-patient group remains unknown ahead of Saturday's session.

"The Phase 2 benchmark creates lofty expectations," Mitchell Kapoor, a senior analyst at H.C. Wainwright, told BioSpace. "The real test here is how much of that extraordinary Phase 2 effect survives when the patient numbers scale from 157 patients to more than 1,100."

What Doctors and Patients Are Watching For

The presentation has been scheduled for the ESMO Presidential Symposium, a prominent session reserved for studies that have the potential to alter the standard of medical care. Following the August topline announcement, Moderna's stock rose 284%, making it one of the top performers in the S&P 500 this year, Morningstar reported. Still, practicing physicians emphasize that seeing the detailed numbers is necessary before drawing firm conclusions for clinical care.

"I hope we get to see what the magnitude of benefit is," Dr. Daniel Olson, an oncologist at the UChicago Medicine hospital system, one of the trial sites, told Morningstar. "That will really tell us: Is this something that we want to move forward and bring into the clinic?"

For patients and families affected by melanoma, several practical realities remain important to keep in mind:

  • Current availability: The vaccine is not yet approved by the U.S. Food and Drug Administration (FDA) and is not currently available for routine prescription outside of clinical trials.
  • Specific medical use: The current trial data apply specifically to preventing recurrence in stage IIB–IV melanoma after complete surgical removal, not to treating other types of cancer or preventing skin cancer in healthy people.
  • Unanswered clinical questions: Doctors will be looking closely at Saturday's data to see how consistent the benefits are across different melanoma stages, how side effects compare to taking Keytruda alone, and whether the six-week manufacturing turnaround poses any practical hurdles.

Frequently Asked Questions

When could the Moderna and Merck melanoma vaccine become available to patients?

There is no confirmed FDA filing or approval date yet. While Dr. Mehnert told Star News Group she is hopeful the treatment could become an option for the public within a year after researchers present the findings to the FDA, formal regulatory review timelines will depend on the complete dataset presented at ESMO and subsequent agency evaluations.

Does the Phase 3 trial prove that patients live longer overall?

Not yet. The August topline announcement confirmed that the trial met its goals for recurrence-free survival and distant-metastasis-free survival. However, mature data establishing an overall survival benefit from the Phase 3 study have not yet been reported, and researchers will need longer follow-up to determine how strongly fewer recurrences translate into extended life expectancy.

Sources